Long-Term Debt: The sum of all long term debt fields.
Mineralys Therapeutics, Inc. (MLYS) had Long-Term Debt of $97.62M for the most recently reported fiscal quarter, ending 2026-06-30.
| Income Statement Financials | |
-- |
|
$-241.07M |
|
-- |
|
-- |
|
$246.04M |
|
$-246.04M |
|
$4.97M |
|
$-241.07M |
|
$-241.07M |
|
$-241.07M |
|
$-241.07M |
|
$-241.07M |
|
$-241.07M |
|
$-246.04M |
|
$-245.91M |
|
84.73M |
|
84.73M |
|
$-2.85 |
|
$-2.85 |
|
| Balance Sheet Financials | |
$665.80M |
|
$0.03M |
|
$2.05M |
|
$667.85M |
|
$19.32M |
|
|
Long-Term Debt |
$97.62M |
$97.62M |
|
$116.94M |
|
$550.92M |
|
$550.92M |
|
$550.92M |
|
88.35M |
|
| Cash Flow Statement Financials | |
$-72.03M |
|
$-230.16M |
|
$267.54M |
|
$172.92M |
|
$138.27M |
|
$-34.65M |
|
$13.90M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
34.46 |
|
-- |
|
-- |
|
0.15 |
|
0.18 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-72.03M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-43.76% |
|
-43.76% |
|
-36.10% |
|
-37.17% |
|
$6.24 |
|
$-0.85 |
|
$-0.85 |
|